These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 20876828)

  • 1. Ranolazine-tacrolimus interaction.
    Pierce DA; Reeves-Daniel AM
    Ann Pharmacother; 2010 Nov; 44(11):1844-9. PubMed ID: 20876828
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Influence of CYP3A5 and MDR1 polymorphisms on tacrolimus concentration in the early stage after renal transplantation.
    Zhang X; Liu ZH; Zheng JM; Chen ZH; Tang Z; Chen JS; Li LS
    Clin Transplant; 2005 Oct; 19(5):638-43. PubMed ID: 16146556
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Toward personalized medicine in renal transplantation.
    Lampreabe I; Gainza de los Rios FJ; Arrieta Gutiérrez A; Jofre-Monseny L; Rodriguez M; Amenabar Iribar JJ; Zárraga Larrondo S; Tejedor D; Martinez A; Olano-Martin E
    Transplant Proc; 2010 Oct; 42(8):2864-7. PubMed ID: 20970553
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Influence of CYP3A5 genetic polymorphism on tacrolimus daily dose requirements and acute rejection in renal graft recipients.
    Quteineh L; Verstuyft C; Furlan V; Durrbach A; Letierce A; Ferlicot S; Taburet AM; Charpentier B; Becquemont L
    Basic Clin Pharmacol Toxicol; 2008 Dec; 103(6):546-52. PubMed ID: 19067682
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A prospective, open-label, observational clinical cohort study of the association between delayed renal allograft function, tacrolimus exposure, and CYP3A5 genotype in adult recipients.
    Kuypers DR; de Jonge H; Naesens M; Vanrenterghem Y
    Clin Ther; 2010 Nov; 32(12):2012-23. PubMed ID: 21118736
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of oral itraconazole on the pharmacokinetics of tacrolimus in a hematopoietic stem cell transplant recipient with CYP3A5*3/*3.
    Nara M; Takahashi N; Miura M; Saitoh H; Kagaya H; Sawada K
    Am J Hematol; 2010 Aug; 85(8):634-5. PubMed ID: 20568249
    [No Abstract]   [Full Text] [Related]  

  • 7. Optimization of initial tacrolimus dose using pharmacogenetic testing.
    Thervet E; Loriot MA; Barbier S; Buchler M; Ficheux M; Choukroun G; Toupance O; Touchard G; Alberti C; Le Pogamp P; Moulin B; Le Meur Y; Heng AE; Subra JF; Beaune P; Legendre C
    Clin Pharmacol Ther; 2010 Jun; 87(6):721-6. PubMed ID: 20393454
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The interaction between antiretroviral agents and tacrolimus in liver and kidney transplant patients.
    Jain AK; Venkataramanan R; Shapiro R; Scantlebury VP; Potdar S; Bonham CA; Ragni M; Fung JJ
    Liver Transpl; 2002 Sep; 8(9):841-5. PubMed ID: 12200788
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reduced C0 concentrations and increased dose requirements in renal allograft recipients converted to the novel once-daily tacrolimus formulation.
    de Jonge H; Kuypers DR; Verbeke K; Vanrenterghem Y
    Transplantation; 2010 Sep; 90(5):523-9. PubMed ID: 20592652
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genetic polymorphisms and individualized tacrolimus dosing.
    López-Montenegro Soria MA; Kanter Berga J; Beltrán Catalán S; Milara Payá J; Pallardó Mateu LM; Jiménez Torres NV
    Transplant Proc; 2010 Oct; 42(8):3031-3. PubMed ID: 20970601
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacogenetic vs. concentration-controlled optimization of tacrolimus dosing in renal allograft recipients.
    Kuypers DR
    Clin Pharmacol Ther; 2010 Nov; 88(5):595-6; author reply 597. PubMed ID: 20664539
    [No Abstract]   [Full Text] [Related]  

  • 12. Three-month experience with tacrolimus once-daily regimen in stable renal allografts.
    Diez Ojea B; Alonso Alvarez M; Aguado Fernández S; Baños Gallardo M; García Melendreras S; Gómez Huertas E
    Transplant Proc; 2009; 41(6):2323-5. PubMed ID: 19715908
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dosing tacrolimus based on CYP3A5 genotype: will it improve clinical outcome?
    van Gelder T; Hesselink DA
    Clin Pharmacol Ther; 2010 Jun; 87(6):640-1. PubMed ID: 20485320
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of MDR1 and CYP3A5 on the oral clearance of tacrolimus and tacrolimus-related renal dysfunction in adult living-donor liver transplant patients.
    Fukudo M; Yano I; Yoshimura A; Masuda S; Uesugi M; Hosohata K; Katsura T; Ogura Y; Oike F; Takada Y; Uemoto S; Inui K
    Pharmacogenet Genomics; 2008 May; 18(5):413-23. PubMed ID: 18408564
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of coadministered HIV-protease inhibitors on tacrolimus and sirolimus blood concentrations in a kidney transplant recipient.
    Barau C; Blouin P; Creput C; Taburet AM; Durrbach A; Furlan V
    Fundam Clin Pharmacol; 2009 Aug; 23(4):423-5. PubMed ID: 19709321
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical relevance and prevalence of polymorphisms in CYP3A5 and MDR1 genes that encode tacrolimus biotransformation enzymes in liver transplant recipients.
    Barrera-Pulido L; Aguilera-García I; Docobo-Pérez F; Alamo-Martínez JM; Pareja-Ciuró F; Nuñez-Roldán A; Gómez-Bravo MA; Bernardos-Rodríguez A
    Transplant Proc; 2008 Nov; 40(9):2949-51. PubMed ID: 19010156
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ranolazine, tacrolimus, and diltiazem might be a hazardous combination in a transplant patient.
    Patni H; Gitman M; Hazzan A; Jhaveri KD
    Ren Fail; 2012; 34(2):251-3. PubMed ID: 22263871
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Time of drug administration, CYP3A5 and ABCB1 genotypes, and analytical method influence tacrolimus pharmacokinetics: a population pharmacokinetic study.
    Musuamba FT; Mourad M; Haufroid V; Delattre IK; Verbeeck RK; Wallemacq P
    Ther Drug Monit; 2009 Dec; 31(6):734-42. PubMed ID: 19855314
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of voriconazole on tacrolimus metabolism in a kidney transplant recipient.
    Capone D; Tarantino G; Gentile A; Sabbatini M; Polichetti G; Santangelo M; Nappi R; Ciotola A; D'Alessandro V; Renda A; Basile V; Federico S
    J Clin Pharm Ther; 2010 Feb; 35(1):121-4. PubMed ID: 20175821
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Significant impact of gene polymorphisms on tacrolimus but not cyclosporine dosing in Asian renal transplant recipients.
    Loh PT; Lou HX; Zhao Y; Chin YM; Vathsala A
    Transplant Proc; 2008 Jun; 40(5):1690-5. PubMed ID: 18589174
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.